IO BIOTECH INC. - COM

IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine

09 дек 2021 11:05:00 Источник Nasdaq GlobeNewswire

IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

06 дек 2021 08:00:04 Источник Nasdaq GlobeNewswire

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

09 ноя 2021 11:06:22 Источник Nasdaq GlobeNewswire